Developing Next Generation NanoCannabinoid Formulations
SGN NanoPharma is an innovative, clinical-stage and revenue-generating developer of nanotherapeutics. The Company combines proprietary nanotechnologies with structural biology to generate superior solutions by (a) reformulating FDA approved drugs that are sub-optimal and (b) by developing novel therapies.
The Company is committed to the development of nano-cannabinoid candidate products targeting transdermal delivery, increased bioavailability, and reduced psychotropic effects. Our aim is to safely deliver large dose therapies as an alternative to many traditional medicines such as opiates, which are currently considered over prescribed and potentially life-threatening.